Cargando…
Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain
INTRODUCTION: Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there exists a dearth of studies of its tolerability and efficacy, especially in special populations. Former elite athletes are a special population both susceptible to chronic pain and also highly trained and attun...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061782/ https://www.ncbi.nlm.nih.gov/pubmed/36991501 http://dx.doi.org/10.1186/s42238-023-00179-8 |
_version_ | 1785017362346409984 |
---|---|
author | Hall, Nicole James, Bradie Bhuiyan, Mohammad Alfrad Nobel Crane, Erin Falgout, Carlie Murnane, Kevin Sean |
author_facet | Hall, Nicole James, Bradie Bhuiyan, Mohammad Alfrad Nobel Crane, Erin Falgout, Carlie Murnane, Kevin Sean |
author_sort | Hall, Nicole |
collection | PubMed |
description | INTRODUCTION: Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there exists a dearth of studies of its tolerability and efficacy, especially in special populations. Former elite athletes are a special population both susceptible to chronic pain and also highly trained and attuned to assess medication tolerability concerns. The purpose of the present open-label pilot study was to assess the tolerability of CBD in this population. MATERIALS AND METHODS: Retrospective analysis was conducted in deidentified data from 20 individuals who were all previously professional athletes in US/American football, track and field, or basketball, with careers ranging from 4 to 10 years. Participants received topical CBD (10 mg twice daily by controlled dispenser) for chronic pain resulting from acute lower extremity injuries. Assessments of tolerability and secondary analyses of pain, pain-related disability, and activities of daily living were collected by self-report over the 6-week study period. Data were analyzed by descriptive statistics, pairwise t-test, and linear regression. RESULTS: Seventy percent of participants completed the study. Of the individuals who completed the study, 50% reported minor adverse effects, none of which required medical attention, and 50% did not report any adverse effects. The mostly commonly reported effects were skin dryness (43% of study completers) and skin rash (21% of study completers), which rapidly resolved. There was a significant improvement in self-reported pain levels (intake mean 3.5 ± 0.29; exit mean 1.7 ± 0.23; P < 0.001) and pain-related disability, including family and home responsibilities, life support activities, occupational activities, recreational activities, self-care, sexual function, and social activities (all P < 0.001). DISCUSSION: To the best of our knowledge, this is the first study to assess CBD treatment in elite athletes, who are disproportionally susceptible to disabling injuries. Topical administration of CBD was tolerated well by this population and resulted in only minor adverse effects. As elite athletes are trained and attuned to assess their own bodies due to their professional lives, this population is likely to detect tolerability concerns. However, this study was limited to a convenience sample and self-reported data. These pilot findings warrant further study of topical CBD in randomized and controlled studies of elite athletes. |
format | Online Article Text |
id | pubmed-10061782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100617822023-03-31 Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain Hall, Nicole James, Bradie Bhuiyan, Mohammad Alfrad Nobel Crane, Erin Falgout, Carlie Murnane, Kevin Sean J Cannabis Res Original Research INTRODUCTION: Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there exists a dearth of studies of its tolerability and efficacy, especially in special populations. Former elite athletes are a special population both susceptible to chronic pain and also highly trained and attuned to assess medication tolerability concerns. The purpose of the present open-label pilot study was to assess the tolerability of CBD in this population. MATERIALS AND METHODS: Retrospective analysis was conducted in deidentified data from 20 individuals who were all previously professional athletes in US/American football, track and field, or basketball, with careers ranging from 4 to 10 years. Participants received topical CBD (10 mg twice daily by controlled dispenser) for chronic pain resulting from acute lower extremity injuries. Assessments of tolerability and secondary analyses of pain, pain-related disability, and activities of daily living were collected by self-report over the 6-week study period. Data were analyzed by descriptive statistics, pairwise t-test, and linear regression. RESULTS: Seventy percent of participants completed the study. Of the individuals who completed the study, 50% reported minor adverse effects, none of which required medical attention, and 50% did not report any adverse effects. The mostly commonly reported effects were skin dryness (43% of study completers) and skin rash (21% of study completers), which rapidly resolved. There was a significant improvement in self-reported pain levels (intake mean 3.5 ± 0.29; exit mean 1.7 ± 0.23; P < 0.001) and pain-related disability, including family and home responsibilities, life support activities, occupational activities, recreational activities, self-care, sexual function, and social activities (all P < 0.001). DISCUSSION: To the best of our knowledge, this is the first study to assess CBD treatment in elite athletes, who are disproportionally susceptible to disabling injuries. Topical administration of CBD was tolerated well by this population and resulted in only minor adverse effects. As elite athletes are trained and attuned to assess their own bodies due to their professional lives, this population is likely to detect tolerability concerns. However, this study was limited to a convenience sample and self-reported data. These pilot findings warrant further study of topical CBD in randomized and controlled studies of elite athletes. BioMed Central 2023-03-30 /pmc/articles/PMC10061782/ /pubmed/36991501 http://dx.doi.org/10.1186/s42238-023-00179-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Hall, Nicole James, Bradie Bhuiyan, Mohammad Alfrad Nobel Crane, Erin Falgout, Carlie Murnane, Kevin Sean Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
title | Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
title_full | Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
title_fullStr | Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
title_full_unstemmed | Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
title_short | Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
title_sort | topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061782/ https://www.ncbi.nlm.nih.gov/pubmed/36991501 http://dx.doi.org/10.1186/s42238-023-00179-8 |
work_keys_str_mv | AT hallnicole topicalcannabidioliswelltoleratedinindividualswithahistoryofelitephysicalperformanceandchroniclowerextremitypain AT jamesbradie topicalcannabidioliswelltoleratedinindividualswithahistoryofelitephysicalperformanceandchroniclowerextremitypain AT bhuiyanmohammadalfradnobel topicalcannabidioliswelltoleratedinindividualswithahistoryofelitephysicalperformanceandchroniclowerextremitypain AT craneerin topicalcannabidioliswelltoleratedinindividualswithahistoryofelitephysicalperformanceandchroniclowerextremitypain AT falgoutcarlie topicalcannabidioliswelltoleratedinindividualswithahistoryofelitephysicalperformanceandchroniclowerextremitypain AT murnanekevinsean topicalcannabidioliswelltoleratedinindividualswithahistoryofelitephysicalperformanceandchroniclowerextremitypain |